Appointment sheet
Apocrine carcinoma of the breast
Prepared with OnCo (onco.cc/prep/apocrine-carcinoma-breast/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
8 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example ER and PR negative with androgen receptor positive, HER2 status, GCDFP15and FOXA1 expression), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
Triple-negative apocrine carcinoma
- 5.For my situation (triple-negative apocrine carcinoma), which of the standard options do you recommend and why?
- 6.Am I a candidate for Bicalutamide, Enzalutamide, and what side effects should I expect?
Any stage
- 7.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 8.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
The words I may hear
- Androgen receptor-positive triple-negative breast cancer: Some triple-negative breast cancers carry the androgen receptor, the protein that prostate cancer runs on.
- Luminal androgen receptor (LAR) subtype: Luminal androgen receptor is one of the four molecular subtypes of triple-negative breast cancer.
Tests and results to bring
Biomarker results to ask for: ER and PR negative with androgen receptor positive, HER2 status (3+ in two thirds of molecular apocrine tumours), GCDFP15 (gross cystic disease fluid protein 15) and FOXA1 expression.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Triple-negative apocrine carcinoma: As for triple-negative disease of no special type; androgen receptor antagonists only within trials (clinical benefit rates 19 to 33 percent in phase 2). (Bicalutamide, Enzalutamide, Androgen receptor)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call